ME-344

DRUG4 trials

Sponsors

MEI Pharma, Inc., Centro Nacional de Investigaciones Oncologicas CARLOS III

Conditions

Breast CancerColorectal CancerEarly-Stage Breast CarcinomaHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastSolid Tumors

Early Phase 1

ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism

CompletedNCT02806817

Centro Nacional de Investigaciones Oncologicas CARLOS IIIBreast Cancer, Early-Stage Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Start: 2016-07-31End: 2018-11-30Updated: 2019-07-23

Phase 1

Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors

CompletedNCT01544322

MEI Pharma, Inc.Solid Tumors

Start: 2012-05-31End: 2014-08-31Target: 24Updated: 2015-06-18

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

TerminatedNCT02100007

MEI Pharma, Inc.Solid Tumors

Start: 2014-04-30End: 2016-04-30Updated: 2017-10-02

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

TerminatedNCT05824559

MEI Pharma, Inc.Colorectal Cancer

Start: 2023-08-07End: 2024-07-23Updated: 2024-11-21

Related Papers

A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer

Investigational New Drugs2024-12-272 citations

A phase 1b study of the OxPhos inhibitor ME-344 in combination with bevacizumab in refractory metastatic colorectal cancer.

Journal of Clinical Oncology2024-01-20

A randomized phase 0 trial of the mitochondrial inhibitor ME344 or placebo added to the antiangiogenic (Aa) bevacizumab in early HER2-negative breast cancer (E-HERNEBC).

Journal of Clinical Oncology2019-05-201 citations

Abrogation of resistance against bevacizumab (Bev) by mitochondrial inhibition: A phase 0 randomized trial of Bev plus ME344 or placebo in early HER2-negative breast cancer (HERNEBC).

Journal of Clinical Oncology2018-05-205 citations